Trillium Therapeutics Provides Update On Phase I Dose Escalation Study Of CD47 Blocker TTI-622 At ASCO20; Dosing Has Progressed Through First Five Cohorts Up To 4 Mg/Kg Dose Level, Strong Safety Profile, With No Dose-limiting Toxicities Observed
Benzinga Newsdesk